Clinical trials: Diabetes Type I
Diabetic Macular Edema, Macular Edema
MS-553 in Diabetic Retinopathy Patients With Central Involved Macular Edema
This is an open label dose-escalation study to evaluate the safety and treatment benefits of MS-553 in treatment-naive diabetic retinopathy patients with central involved macular edema.
- Conditions
- Diabetic Macular Edema, Macular Edema, Type 2 Diabetes With Diabetic Macular Edema, Type 1 Diabetes With Diabetic Macular Edema
- Trial name
- NCT04187443
- Testing
- MS-553
- Where
- 3 sites in China
- Volunteers
- 45 people
- Sponsor
- Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.
Safety and Tolerability of EGT0001474 in Healthy Volunteers
Study to Determine the Safety, Tolerability, and Pharmacokinetic (PK) Profile of EGT0001474 in Healthy Volunteers
This study evaluated the safety, tolerability and pharmacokinetics of single or multiple doses of EGT0001474.
- Trial name
- NCT00854113
- Testing
- EGT0001474
- Where
- United States
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Theracos
Chronic Kidney Disease
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4248 in Healthy Participants and Participants With Chronic Kidney Disease and Type 2 Diabetes and to Assess Home Measurements of Creatinine in a Non Interventional Cohort
This study will evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses (SAD) and multiple ascending doses (MAD) of AZD4248 administered as an oral solution and intravenous (IV)…
- Trial name
- NCT07024823
- Testing
- AZD4248
- Where
- 5 sites in United States
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Type II Diabetes
Safety, Pharmacokinetics, and Food Effect of PS1 in Subjects
This is a phase I, double-blind, placebo-controlled, randomized, single- and multiple-ascending dose study to evaluate new study intervention, PS1.
- Trial name
- NCT05176210
- Testing
- PS1
- Where
- Taiwan
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Pharmasaga Co. Ltd.
Type 2 Diabetes
To Evaluate the Hormonal Response to Low Blood Sugar After a Single Oral Dose of AZD1656 Suspension
To evaluate the hormonal response to low blood sugar after a single oral dose of AZD1656 suspension.
- Trial name
- NCT00790153
- Testing
- Insulin, AZD1656
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Type 1 Diabetes
Safety Evaluation of an Advanced Hybrid Closed Loop System Using Lyumjev With the Tandem t:Slim X2 Insulin Pump With Control-IQ Technology in Adults, Adolescents and Children With Type 1 Diabetes
Prospective, multi-center, single-arm study in adults and children ages 6 to 80 with type 1 diabetes to evaluate the safety of Lyumjev with Control-IQ technology to achieve labeling updates for Lyumjev and the t:slim X2 insulin…
- Trial name
- NCT05403502
- Testing
- t:slim X2 insulin pump with Control-IQ technology 1.5
- Where
- 13 sites in United States
- Volunteers
- 183 people
- Sponsor
- Tandem Diabetes Care, Inc.
Diabetes Mellitus
A Study Evaluating the Bioequivalence of VIAject®7 Compared to VIAject®25 and Comparing the Pharmacokinetic and Pharmacodynamic Properties of VIAject®7 to Insulin Lispro in Subjects With Type 1 Diabetes Mellitus
The primary objective of this study is to test for bioequivalence of VIAject®7 and VIAject®25 and to compare the pharmacokinetic/Pharmacodynamic/tolerability characteristics of VIAject®7 with those of VIAject®25 and insulin…
- Trial name
- NCT01235039
- Testing
- VIAject®25, VIAject®7, Insulin Lispro
- Where
- Germany
- Volunteers
- 43 people
- Sponsor
- Biodel
Type 2 Diabetes
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HRS9531 in Healthy Subjects
The study is being conducted to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple subcutaneous injections of HRS9531 in healthy subjects.
- Trial name
- NCT05152277
- Testing
- HRS9531
- Where
- China
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Type 1 Diabetes
Comparison of Exposure and Activity of SAR341402 Mix 70/30 to NovoLog Mix 70/30, NovoMix 30 and SAR341402 Rapid-acting Solution in Patients With Type 1 Diabetes Mellitus
Primary Objectives: To demonstrate similarity in exposure of SAR341402 Mix 70/30 to NovoLog Mix 70/30 and NovoMix 30 (cohort 1).
- Trial name
- NCT03916601
- Testing
- SAR341402, Insulin Aspart
- Where
- Germany
- Volunteers
- 52 people
- Sponsor
- Sanofi
Type I Diabetes Mellitus
Phase 4 Study to Evaluate Treatment Optimization With Once-daily Insulin Glargine 300 U/mL
Primary Objective: To evaluate the efficacy of switching treatment from twice-daily basal insulin to once-daily insulin glargine (U300) as part of basal bolus regime in terms of glycated hemoglobin improvement (reduction by at…
- Trial name
- TOP1 (NCT03406000)
- Testing
- INSULIN GLARGINE (U300)
- Where
- 11 sites in Brazil
- Volunteers
- 170 people
- Sponsor
- Sanofi
Type 1 Diabetes Mellitus
Extension Study to Assess Safety and Efficacy of Mylan's Insulin Glargine and Lantus® in Type 1 Diabetes Mellitus (T1DM) Patients
The aim of this extension study is to assess the safety and efficacy of Mylan's insulin glargine and Lantus® in T1DM patients.
- Trial name
- NCT02666430
- Testing
- Mylan's insulin glargine, Lantus®
- Where
- 81 sites in United States, Canada and 6 more
- Volunteers
- 127 people, healthy volunteers welcome
- Sponsor
- Mylan Inc.
Diabetic Retinopathy
A Study to Investigate the Efficacy and Safety of RG7774 in Patients With Diabetes Mellitus Type 1 or Type 2 With Treatment-Naive Diabetic Retinopathy
The study's main purpose is to asses the safety, tolerability, and effect of oral administration of RG7774 on the severity of diabetic retinopathy (DR) in participants with moderately severe to severe non-proliferative diabetic…
- Trial name
- CANBERRA (NCT04265261)
- Testing
- RG7774
- Where
- 68 sites in United States, Australia and 5 more
- Volunteers
- 139 people
- Sponsor
- Hoffmann-La Roche
Type 1 Diabetes
Study Comparing Effectiveness of Intraperitoneal Insulin Administration to Subcutaneous Insulin Administration
The purpose of this study is to evaluate the effectiveness of insulin delivered in the peritoneum (abdomen)by an implantable pump in Type 1 diabetics.
- Trial name
- MIP310 (NCT00211536)
- Testing
- Medtronic MiniMed Implantable Pump Human Recombinant Insulin, Medtronic MiniMed Implantable Pump System, Aventis HOE21PH U400
- Where
- 5 sites in United States
- Volunteers
- 107 people
- Sponsor
- Medtronic MiniMed, Inc.
Type 1 Diabetes Mellitus
A Study Comparing LY900014 to Insulin Lispro (Humalog) in Children and Adolescents With Type 1 Diabetes
The reason for this study is to compare the study drug LY900014 to insulin lispro (Humalog) in children and adolescents with type 1 diabetes (T1D).
- Trial name
- PRONTO-Peds (NCT03740919)
- Testing
- LY900014, Insulin Lispro, Insulin Glargine
- Where
- 111 sites in United States, Austria and 16 more
- Volunteers
- 751 people
- Sponsor
- Eli Lilly and Company
Diabetes, Diabetes Mellitus, Type 1
Comparison of NN1250 Plus Insulin Aspart With Insulin Glargine Plus Insulin Aspart in Type 1 Diabetes
This trial is conducted in Africa, Europe and the United States of America (USA). The aim of the trial is to compare NN1250 (insulin degludec, soluble insulin basal analogue (SIBA)) plus insulin aspart with insulin glargine…
- Trial name
- BEGIN™ (NCT00982228)
- Testing
- insulin degludec, insulin glargine, insulin aspart
- Where
- 91 sites in United States, France and 4 more
- Volunteers
- 629 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1
Empa Add on to Insulin in Japanese Patient With Type 1 Diabetes Mellitus
To assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of once daily oral doses of empagliflozin in Japanese patients with type 1 diabetes mellitus as adjunctive therapy to insulin.
- Trial name
- NCT02702011
- Testing
- empagliflozin medium dose, empagliflozin low dose, empagliflozin high dose
- Where
- 4 sites in Japan
- Volunteers
- 48 people
- Sponsor
- Boehringer Ingelheim
Type 1 Diabetes
Autologous Immunoregulatory Dendritic Cells for Type 1 Diabetes Therapy
The purpose of this study is to determine whether dendritic cells collected via leukapheresis and incubated with antisense DNA oligonucleotides and then injected back into the same subject will serve as modulators of the immune…
- Trial name
- NCT02354911
- Testing
- Immunoregulatory Dendritic Cells
- Sponsor
- DiaVacs, Inc.
Type 1 Diabetes Mellitus
A Trial to Investigate Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BioChaperone® Pramlintide Insulin in Patients With Type 1 Diabetes Mellitus
This is a single center, randomised, double-blind, active comparator controlled, three-period cross-over, single dose trial in subjects with type 1 diabetes mellitus.
- Trial name
- NCT03512236
- Testing
- BC Pram Ins, Symlin® and Humulin®, Humalog®
- Where
- Germany
- Volunteers
- 24 people
- Sponsor
- Adocia
Type 1 Diabetes
Open-label Investigation of the Safety and Efficacy of DIABECELL in Patients With Type 1 Diabetes Mellitus
The purpose of this study is to establish the efficacy and safety of xenotransplantation of DIABECELL [immunoprotected (alginate-encapsulated) porcine islets] in patients with established type 1 diabetes mellitus
- Trial name
- NCT01736228
- Testing
- DIABECELL
- Where
- Argentina
- Volunteers
- 14 people
- Sponsor
- Living Cell Technologies
Diabetes, Diabetes Mellitus, Type 1
Investigation of Pain During Subcutaneous Injections With Different Injection Speed and Volume Combinations
This trial is conducted in Europe. The aim of this trial is to assess and describe the pain in relation to subcutaneous (under the skin) injection of different combinations of injection speed and volume with respect to acceptance…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Delivery Systems
- Trial name
- NCT01680328
- Testing
- 19 injections, sodium chloride 0.9% solution
- Where
- Germany
- Volunteers
- 82 people
- Sponsor
- Novo Nordisk A/S
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.